Entrada Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Source: Globenewswire
New Employee Inducement Grants: Entrada Therapeutics announced the granting of 54,360 restricted stock units and options to purchase 38,850 shares to seven new non-executive employees as part of its 2025 Inducement Equity Plan, with options priced at $5.47 per share, effective September 1, 2025.
Company Overview: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies that target intracellular mechanisms, with a portfolio aimed at treating neuromuscular and ocular diseases, including programs for Duchenne muscular dystrophy and myotonic dystrophy type 1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
